Connect
← Return to Mayo's Article on Treating Prostate Cancer 17 October 2025
Discussion
Mayo's Article on Treating Prostate Cancer 17 October 2025
Prostate Cancer | Last Active: Apr 4 9:13pm | Replies (20)Comment receiving replies
The research was done at Mayo, so there is a great deal of credibility with the study and assumptions. Proton radiation for Gleason 3 plus 3, PSA: 6.47 at Loma Linda Hospital, a pioneer in proton radiation therapy. Spent 2.5 months or 50 morning visits to the "proton machine". For seven (7) years, PSA was below 1.0, then PSA began to rise. Both the PET scan and MRI in May of 2025 was not conclusive to the recurrence of the disease. Having had 15 years to read and research this very common male disease does provide a base of conclusions, to wit: every man is different as to the effect of the disease. The PET scan with the injection of the chemical is designed to attach to high-protein mass cells, which are normally found with cancer cells. The Gleason score is a subjective assessment of the cell structure and the deterioration of that cell because of the cancer. The article from Mayo research implies that some chemicals, perhaps natural, can inhibit the cancer cell growth. The article indicates Sulforaphane is such a natural "chemical".
I just bought a product high in sulforaphana in pill form and will take it for several months daily and measure the PSA from the last result.
Read the Mayo Clinic study again and use AI with word phrases to better understand the intent and meaning. It takes a while, but it's worth the time. If you have communication with your physical, ask about this study.or better yet, send him/her the link. If anything not said here, pass along to the rest of the group members. Cheers!
Replies to "The research was done at Mayo, so there is a great deal of credibility with the..."
Connect
@westernflyer
Thanks for the additional details.
Found the original research paper and ran it through perplexity.ai to find its connection to sulforaphane.
This research paper indicates that sPOM121 boosts the expression of β-catenin, leading to PCa tumor progression and immune evasion.
Inhibiting the sPOM121/β-catenin axis, in preclinical prostate cancer models, halted tumor aggressiveness and strengthened antitumor immunity.
Apparently, Sulforaphane also acts as a Wnt/β-catenin pathway inhibitor, thus the connection you suggest.
However, this particular research paper did not directly investigate sulforaphane, much less suggest a dosage.
Upon further investigation, I found an unrelated Human Clinical Trial investigating the impact of sulfuraphane in BCR. A short AI summary is outlined below:
https://pmc.ncbi.nlm.nih.gov/articles/PMC4390425/
Phase II Trial in Biochemical Recurrence (NCT01228084)
• Formulation: Sulforaphane-rich broccoli sprout extract capsules (each 50 µmol sulforaphane).
• Dose: 200 µmol daily, taken orally as four 50 µmol capsules before breakfast.
• Duration: 20 weeks.
• Outcome: Well tolerated (no grade 3/4 toxicity); about 35% showed modest PSA declines or slowing of PSA doubling time.
A 200 µmol sulforaphane daily dosage (used in this study), is about 3.5-4 ounces of raw, freshly sprouted broccoli (one loosely packed cup) per day.
I like the taste of broccoli sprouts and I started eating one cup per day about 3 months after I was diagnosed in October 2023.
My PSA level dropped from 7.8 (May 2023 - prebiopsy) to 5.8 by February 2024.
Of course, I implemented many diet and exercise changes in the first 3 months after diagnosis, so there is likely to be multiple explanations.
My latest PSA level was 5.76, unchanged over 16 months.
As there appears to be some solid science behind sulfuraphane and now a potential mechanism, I’ll have to add some credit to my broccoli sprouts and HIT to explain my slowing PSA velocity…
Thanks again for this reference!
All the best!